95 results about "Preeclampsia" patented technology

The invention relates to the field of noninvasive prenatal diagnosis, and particularly discloses a preeclampsia noninvasive screening method based on deep sequencing 8bp oligonucleotide double-fragment characteristics, which comprises the following steps: collecting preeclampsia and healthy pregnant woman peripheral blood samples, and extracting free DNA for high-throughput sequencing; the method comprises the following steps: extracting core 8-mer sequences' GTGCGCCC 'and' GATGGGGT 'in a long fragment of 150-200bp through bioinformatics analysis; an integrated support vector machine, K-nearest neighbor, extreme gradient lifting, a random forest and a multi-layer perceptron are combined with a logistic regression element classifier to construct a stacking model, the frequency of a core sequence is normalized, machine learning analysis is carried out, and the preeclampsia risk is predicted. According to the invention, two 8bp oligonucleotide characteristic fragments are specifically screened, and a deep learning architecture of multi-model fusion is combined, so that the limitations of low specificity and invasive detection of a traditional screening method are effectively broken through.

The invention discloses a pre-eclampsia prediction method and system based on machine learning and early pregnancy indexes. The pre-eclampsia prediction method comprises the following steps: acquiring early pregnancy laboratory index data and FMF model evaluation parameters of a to-be-predicted pregnant woman; based on a preset preeclampsia type, performing feature screening on the early pregnancy laboratory index data by using a Boruta algorithm to construct corresponding original features; inputting the original features into a trained first-level machine learning prediction model corresponding to the pre-eclampsia type to obtain a risk score; according to the risk score and an FMF model evaluation parameter, obtaining a joint feature; and inputting the joint features into a trained second-stage machine learning prediction model corresponding to the pre-eclampsia type to obtain a corresponding pre-eclampsia risk prediction result. According to the method, information of different sources and different physiological dimensions is deeply fused, analyzed and judged, and high-precision and low-cost early prediction of different pre-eclampsia types is realized.

The disclosure describes changes in cfRNA gene expression that are associated with risk for preeclampsia. Accordingly, the disclosure provides methods and kits for preeclampsia risk assessment.

The invention discloses a wearable monitoring bracelet for preeclampsia early warning, and relates to the technical field of wearable monitoring bracelets.The wearable monitoring bracelet comprises a monitoring bracelet body, a touch control circular screen is arranged in the middle of the top face of the monitoring bracelet body, and splicing end blocks are fixedly connected to the two ends of the monitoring bracelet body; the end parts of the two splicing end blocks are both provided with expansion splicing boxes, the interior of the expansion splicing box at the tail end of the monitoring bracelet main body is filled with an installation elastic rubber box, and one side of the interior of the installation elastic rubber box is provided with a gas pressure intensity sensor. Meanwhile, a universal splicing structure is utilized at the splicing part of the expansion splicing box and the splicing end block, so that a sensor in the expansion splicing box can be replaced as required, and the monitoring bracelet can be used for specially and accurately detecting other vital signs while detecting eclampsia symptoms; and the use safety and smoothness of the monitoring bracelet are further improved.

The invention discloses a method and a system for predicting preeclampsia risk of a pregnant woman based on computer implementation. The method integrates the concentration level of vitamin D (especially 25-hydroxyvitamin D) in serum of pregnant women, angiogenesis biomarkers (such as sFlt-1 / PlGF ratio), conventional clinical indexes (such as mean arterial pressure and body mass index) and personal medical history data. A machine learning algorithm (such as a random forest or a gradient lifting model) is adopted to carry out weighted analysis on the multi-dimensional data, and a dynamic and high-precision prediction model is constructed. The system comprises a data acquisition module, an intelligent prediction module and a clinical decision support module, and can provide real-time risk assessment and personalized intervention suggestions (such as a vitamin D supplement scheme) for medical staff, so that early warning and effective management of preeclampsia are realized, and the risk of pregnancy outcome caused by maternal and infant poor pregnancy is reduced.

The invention discloses a urine glycosylation protein marker for early auxiliary diagnosis of preeclampsia and application of the urine glycosylation protein marker. The invention discloses a urine glycosylation protein marker for early auxiliary diagnosis of preeclampsia. The urine glycosylation protein marker is selected from any one or more of glycosylation modified SERPINC1 and SERPING1. The invention also discloses application of the reagent for detecting the urine glycosylated protein marker in preparation of a kit for early auxiliary diagnosis of preeclampsia. According to the present invention, the high-throughput screening method is adopted to analyze the glycosylated proteins in the urine of the normal pregnancy pregnant woman and the preeclampsia pregnant woman, such that the glycosylated proteins capable of indicating the preeclampsia disease are screened, and the research basis is provided for the development and the clinical application of the glycosylated protein marker in the urine; besides, in the research method, urine is relatively simple and non-invasive to collect and is easier to obtain, so that the urine is easier to accept by a patient, continuous dynamic monitoring can be performed, changes of markers can be tracked, clinical transformation is easy, and the method is suitable for popularization and application.

The invention provides a computer-implemented method for predicting and assessing a health risk parameter, such as the risk of diabetes, in particular gestational diabetes and / or preeclampsia, of a woman based on at least one pregnancy-related parameter, the method comprising the steps of: if the pregnancy-related parameter satisfies a first condition; if so, providing an assessment of the health risk parameter using a first machine learning model (1); providing an assessment of the health risk parameter using a second machine learning model (2) if the pregnancy-related parameter satisfies a second condition; and the health risk parameters are made available.

Provided are diagnostic and / or screening tests, assays and devices for preeclampsia (PE). The diagnostic and / or screening tests, assays and devices include test antibodies for activin A and / or inhibin A. The PE diagnostic and / or screening tests, assays and devices are capable of detecting activin A and / or inhibin A in a sample at a concentration of less than about 60 pg / mL. Corresponding methods of diagnosing and / or screening for PE are provided.

The invention provides an application of a pair of immune costimulatory factors TNFSF9 / TNFRSF9 as markers in preparation of a product for early prediction of preeclampsia, and the immune costimulatory factors comprise a tumor necrosis factor superfamily member 9 (TNFSF9) and a tumor necrosis factor receptor superfamily member 9 (TNFRSF9). The product is used for carrying out early warning on the preeclampsia occurrence risk 20 weeks before pregnancy. The product is used for detecting the immune costimulatory factor through at least one of serum, plasma, whole blood and placental tissue. The invention aims to improve the early prediction efficiency of preeclampsia by detecting the abnormal expression level of the pair of markers.

Provided are methods and compositions for using tissue kallikrein-1 (KLK1) to treat or prevent pregnancy disorders such as fetal growth restriction (FGR) and preeclampsia.

The invention discloses a machine learning-based pregnant woman preeclampsia subtype classification probability prediction method and system. According to the method, the one-carbon metabolic cycle core metabolite is combined with multi-source clinical indexes for the first time, and cross-modal deep feature fusion is realized by constructing derivative composite features with clear biological significance; in the model level, a double-layer self-adaptive model integration strategy is adopted, firstly, multiple base classifiers are subjected to self-adaptive weighted fusion based on cross validation performance, then further optimization is carried out through stacking generalization, and a final prediction model with high precision and high robustness is formed; besides, the system integrates SHAP interpretability analysis and risk positioning visualization based on historical distribution, not only outputs the classification probability, but also provides visual clinical decision-making assistance. According to the method, the problems of insufficient subtype identification ability, weak model generalization ability and poor result interpretability in the prior art are effectively solved, and reliable technical support is provided for health management and clinical decision-making in the gestation period.

The invention discloses a preeclampsia biomarker and an application of the preeclampsia biomarker. The preeclampsia biomarker comprises at least one of a fusion gene PSPC1-MRPS31P2 and a fusion gene LINC00630-AL035494. The preeclampsia biomarker can be used for detecting preeclampsia. The preeclampsia biomarker provided by the invention can provide a non-invasive diagnosis scheme for clinical prenatal preeclampsia, and preeclampsia specific high-expression fusion genes (PSPC1-MRPS31P2 and LINC00630-AL035494) in peripheral blood of a pregnant woman are detected through real-time quantitative PCR (Polymerase Chain Reaction), so that preeclampsia early prediction, disease diagnosis and monitoring of the state of a patient in the illness period are realized; and in combination with the existing clinical diagnosis scheme, the accuracy of pre-eclampsia diagnosis is improved.

The application provides use of zanamivir in preparation of a medicine for treating or preventing preeclampsia, and a corresponding medicine and treatment method; zanamivir can effectively improve high blood pressure, proteinuria, creatinine, neuraminidase and sialic acid elevation symptoms of preeclampsia, increase NO level, and improve pregnancy outcome. Zanamivir and hydroxyprogesterone caproate in combination show better effects.

The invention is suitable for the technical field of biology, and provides an L-NAME induced trophoblast organ injury model and a construction method and application thereof, and the construction method of the trophoblast organ injury model comprises the following steps: constructing a trophoblast organ by using human villus tissue; the method comprises the following steps: carrying out culture and passage treatment on a trophoblast organ, and then adding L-NAME with the final concentration of 15-60mM to carry out induced injury, so as to obtain the trophoblast organ injury model. The basic model used in the invention is a trophoblast-like organ which can be subcultured for a long time, so that the problems of difficult acquisition of placenta samples and ethics limitation in the clinical early stage are reduced. Meanwhile, L-NAME is used for performing drug-induced injury, a trophoblast organ injury model for simulating the placental pathological state of preeclampsia can be constructed, and compared with traditional hypoxia-induced injury, the method is more convenient, and the limitation of instruments and equipment is reduced.

The invention discloses application of C1INH in preparation of a product for prediction or auxiliary diagnosis of preeclampsia and the product, belongs to the technical field of biological medicines, and aims to detect the content of C1INH in a blood sample on a protein level by taking the blood sample of a subject as a detection object. According to the invention, C1INH molecules in blood are taken as a detection index, prediction and auxiliary diagnosis of preeclampsia of pregnant women can be realized, high sensitivity and specificity are realized, rapid detection can be realized, and a new way is provided for early screening and diagnosis of preeclampsia in the prior art.

This invention discloses a method, prediction method, and prediction device for constructing a preeclampsia prediction model based on temporal multimodal data, relating to the field of preeclampsia risk prediction technology. The construction method includes: acquiring multimodal temporal feature data of pregnant women with known pregnancy outcomes to construct a time-series dataset; the pregnant women with known pregnancy outcomes include those with and without preeclampsia; training a graph attention network and a fully connected network using the time-series dataset; embedding the resulting missing value fitting model as an embedding layer into a gated recurrent unit; and obtaining the preeclampsia prediction model after training with the time-series dataset. In this invention, the prediction model processes missing data through a missing value fitting model, effectively recovering missing information and ensuring the model can more accurately handle incomplete medical data. Simultaneously, the combination of a gated recurrent unit for capturing and predicting temporal features effectively improves the prediction accuracy of preeclampsia.

The invention relates to a computer-implemented method for classification of an occurrence of a complication caused by preeclampsia within a predetermined time period, comprising applying (S3) a second machine learning algorithm (A2) to the second dataset (DS2) of medical parameters of the patient to classify the occurrence of the complication caused by preeclampsia within the predetermined time period, and outputting (S4) a class representing the occurrence of the complication caused by preeclampsia within the predetermined time period. The invention further relates to a system (1) for classification of an occurrence of a complication caused by preeclampsia within a predetermined time period.

The present application relates to the technical field of medical data fusion processing, and discloses a method and system for predicting adverse pregnancy outcomes of preeclampsia by fusing placental microenvironment image features and serum biomarkers, wherein the method comprises: obtaining digital whole field image of placental tissue section and serum biomarker detection data at the same period; constructing a multi-modal sample data set; extracting multi-scale structure features of placental microenvironment; constructing serum biomarker discriminant features; dynamically fusing placental image features and serum marker features; constructing a prediction model for adverse pregnancy outcomes of preeclampsia and outputting a prediction probability. Compared with the prior art which only relies on single image information or single serum biomarker for risk assessment, it is difficult to realize stable prediction of the coordinated changes of placental microenvironment abnormalities and biochemical abnormalities. Due to the multi-scale image structure analysis, the model generalization ability for predicting adverse pregnancy outcomes of preeclampsia is improved.

The present invention includes methods and computer programs for use in the detection preeclampsia and / or determining an increased risk for preeclampsia in a pregnant female, the methods including identifying in a biosample obtained from the pregnant female cell-free DNA signals, including concentration, fetal fraction, and fragment size distribution. These methods provide for the identification of patients at risk of preeclampsia in the first trimester of pregnancy.

Provided are methods and compositions for using tissue kallikrein-1 (KLK1) to treat or prevent pregnancy disorders such as fetal growth restriction (FGR) and preeclampsia.

Provided is a method for diagnosing or predicting preeclampsia in a pregnant woman or determining if a pregnant woman has a risk of preeclampsia, comprising: a) obtaining at least one (such as two or more) maternal or fetal parameter or factor of the pregnant woman, selected from a group comprising: (i) one or more of mean artery pressure (MAP), BMIsampling, ΔBMI, Gestational age and ΔBMI / GA; (ii) Maternal age; (iii) one or more of Urinary protein level and the ratio of Urinary protein level (such as Urine Total Protein (UTP) ) / Urinary Creatinine level (Cre) (UTP / Cre); (iv) one or more of preeclampsia in previous pregnancy (PEhis) and having received antihypertensive medication (Antihyper); and (v) any combination of (i) - (iv), b) determining if the urine of said pregnant woman contains misfolded proteins or misfolded protein aggregates, and c) combining the at least one maternal or fetal parameter or factor obtained in step a) and the content level of misfolded proteins or misfolded protein aggregates in the urine of said pregnant woman to diagnose or predict preeclampsia or determine the risk of preeclampsia.

The application discloses a preeclampsia diagnosis and treatment biological marker and application thereof; the application deeply demonstrates the mechanism that high expression DHRS4 causes PE by inhibiting the invasiveness of trophoblasts from the clinical sample, cells and in vivo level, and overexpression DHRS4 in the application combines and up-regulates LONP2, degrades TFAM protein through ubiquitination, causes mitochondrial dysfunction, weakens the migration and invasion ability of trophoblasts, participates in the mechanism of PE occurrence, is a new mechanism clue obtained according to the pre-experiment results and information analysis, is a new target for deeply exploring the clinical diagnosis and treatment of PE, and the research result can provide a theoretical basis for guiding the early prediction and intervention of PE in the future.

The present disclosure relates to a method and device for predicting the risk of preeclampsia by utilizing an artificial intelligence model. One embodiment of the present disclosure may provide a method for predicting the risk of preeclampsia by utilizing an artificial intelligence model, the method comprising the steps of: inputting data about an expectant mother to a preeclampsia prediction model generated on the basis of a training data set; and acquiring an incidence rate of the preeclampsia from the preeclampsia prediction model, wherein the data about the expectant mother includes final variables determined from a plurality of initial variables of the training data set.

Described herein are lateral flow devices, kits, systems and methods for measuring levels of sFlt-1 in a plasma or serum sample and prognosticating a women's risk of having sPE.

The invention relates to a compound as shown in a formula (I), a stereoisomer, a tautomer, an isotope label, nitrogen oxide, a solvate, a polymorphic substance, pharmaceutically acceptable salt or prodrug of the compound, a preparation method of the compound, and a pharmaceutical composition of the compound and the stereoisomer, the tautomer, the isotope label, the nitrogen oxide, the solvate, the polymorphic substance and the pharmaceutically acceptable salt or prodrug. In particular, the compounds are NK-3 receptor antagonists, the compound can be used for preventing and / or treating depression, anxiety disorder, psychosis, schizophrenia, psychotic disorder, bipolar disorder, cognitive disorder, Parkinson's disease, Alzheimer's disease, attention deficit hyperactivity disorder, pain, convulsion, obesity, inflammatory diseases, vomiting, pre-eclampsia, airway-related diseases, reproductive disorders, contraception and sex hormone dependent diseases, and can be used for preventing and / or treating diseases such as chronic bronchitis and chronic bronchitis. , gynecological diseases, and climacteric syndrome.

The present invention relates to a disease-specific biomarker for early prediction and diagnosis of preeclampsia and use thereof, and a composition for prediction or diagnosis of preeclampsia according to an aspect or a method of providing information for prediction or diagnosis thereof, can simply and effectively predict or diagnose the disease by measuring and comparing the mRNA level of a disease-specific protein or a gene encoding the protein changed in a patient.

This disclosure relates to improved detection of predictors of preeclampsia.

The present invention includes methods and materials for use in the detection preeclampsia and / or determining an increased risk for preeclampsia in a pregnant female, the method including identifying in a biosample obtained from the pregnant women a plurality of circulating RNA (C-RNA) molecules.

The invention provides a gene marker combination and application thereof in a risk prediction model of premature eclampsia. The gene marker combination comprises a combination selected from GTF2H1, CD48, PBX1, PLA2G2A, ACVR1B, HMGB1, ERBB2, XRCC5, TGFBR2, NFKB1, EGF, TLR6, EZH2, IKZF1, EGFR and CD36, a combination of HIPK1, MTHFR, IL6R, RAB27A, UBE2I, CREBBP, SOX8, HNF4A, ICOS, LIF, TMPRSS6, DNMT3A, WWTR1, RASSF1, FOXP1, TLR2 and MAPK14, AGRN, ATP2B1, ELAC2, HDAC5, GABARAP, FXR2, NFE2L2,

The present invention relates to the use of 6-gingerol in the preparation of a medicament for treating preeclampsia, belonging to the technical field of medicine. The present invention provides the use of 6-gingerol in the preparation of a medicament, health food or special medical food for treating preeclampsia. 6-Gingerol blocks the initiation of mitophagy by reducing the expression of BNIP3 and LC3, or regulates H / R-induced mitophagy by inhibiting the production of mitochondrial ROS, thereby playing a role in treating or preventing preeclampsia medicaments. The present invention discovers for the first time that 6-gingerol can block the initiation of mitophagy by reducing the expression of BNIP3 and LC3 or regulate H / R-induced mitophagy by inhibiting the production of mitochondrial ROS, so as to achieve the purpose of treating or preventing preeclampsia.